A meta-analysis based on 18 studies involving more than 2000 patients with ovarian cancer demonstrated that the expression of CD44 correlated with a high TMN (Classification of Malignant Tumour) stage and a poor 5-year overall survival. This evidence concerns the gene CD44 and ovarian carcinoma.